

Application No.: 10/550,039
Amendment Dated: August 10, 2006
Page 11 of 12


RECEIVED
CENTRAL FAX CENTER
AUG 10 2006

Remarks/Arguments

Claims 1, 4, 5, 6, 7, 9, 12, 13, and 14 are pending and under examination. Applicants have herewith amended claims 1, 7, and 13 to be of a scope consistent with Applicants' elected group. No new matter has been added by these amendments.


Applicants were orally requested by the Examiner to elect a group for examination. Applicants' undersigned representative discussed this restriction requirement during an August 7, 2006 telephone conversation with the Examiner. In that conversation, Applicants orally elected for examination the group drawn to a compound of formula (I) wherein:

1. -N-HET is:



(Id);


2. Q is



Q1; and

3. a composition thereof, and process of making.

The following compound was orally elected by Applicants for the purpose of the Examiner's searching:



Application No.: 10/550,039
Amendment Dated: August 10, 2006
Page 12 of 12

BEST AVAILABLE COPY

This compound is disclosed on page 56 the specification as Example 1, and is a species within the scope of amended claim 1.

The above remarks have been made without prejudice to Applicants right to prosecute any withdrawn subject matter in a timely filed continuation application. Applicants believe the application is in condition for allowance and reserve the right to prosecute any canceled subject matter in timely filed continuation applications.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100870-1P US.

Respectfully submitted,



Name: John X. Haberman
Dated: August 10, 2006
Reg. No.: 55,236
Phone No.: 781-839-4736
Global Intellectual Property, Patents
AstraZeneca R&D Boston
35 Gatehouse Drive
Waltham, MA 02451-1215